2抑制剂-话题@MedSci

#2抑制剂#

221篇内容 | 4046人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1995627, encodeId=cfff199562efc, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=美国FDA授予Bcl-2抑制剂APG-2575第五个孤儿药称号，用以治疗滤泡性淋巴瘤（FL）, objectType=article, longId=206517, objectId=375420651efe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=375420651efe, replyNumber=0, likeNumber=63, createdTime=2021-07-28, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=375420651efe, moduleTitle=美国FDA授予Bcl-2抑制剂APG-2575第五个孤儿药称号，用以治疗滤泡性淋巴瘤（FL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=375420651efe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995632, encodeId=d9481995632f3, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=亚盛医药APG-2575临床优势初显，国内首家Bcl-2抑制剂用于CLL/SLL前景无限, objectType=article, longId=212474, objectId=868f2124e4b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=868f2124e4b8, replyNumber=0, likeNumber=75, createdTime=2022-04-30, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=868f2124e4b8, moduleTitle=亚盛医药APG-2575临床优势初显，国内首家Bcl-2抑制剂用于CLL/SLL前景无限, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=868f2124e4b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995634, encodeId=6a181995634f6, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=NEJM：谷氨酰胺转胺酶2抑制剂治疗乳糜泻概念验证研究获得成功, objectType=article, longId=213720, objectId=c4b0213e20fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4b0213e20fe, replyNumber=0, likeNumber=83, createdTime=2021-11-19, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4b0213e20fe, moduleTitle=NEJM：谷氨酰胺转胺酶2抑制剂治疗乳糜泻概念验证研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4b0213e20fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995639, encodeId=1b5e1995639d8, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=SGLT2抑制剂Forxiga获得欧盟和英国的批准，用于治疗慢性肾病, objectType=article, longId=215519, objectId=1da5215519ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1da5215519ba, replyNumber=0, likeNumber=69, createdTime=2021-10-07, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1da5215519ba, moduleTitle=SGLT2抑制剂Forxiga获得欧盟和英国的批准，用于治疗慢性肾病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1da5215519ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995641, encodeId=eeea199564147, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=JAHA：2型糖尿病患者的钠-葡萄糖协同转运蛋白2抑制剂、全因死亡率和心血管结局, objectType=article, longId=217061, objectId=cf3921e0617e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf3921e0617e, replyNumber=0, likeNumber=76, createdTime=2022-01-19, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf3921e0617e, moduleTitle=JAHA：2型糖尿病患者的钠-葡萄糖协同转运蛋白2抑制剂、全因死亡率和心血管结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf3921e0617e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995628, encodeId=48bc199562801, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Neuro Oncol：MEK-1/2抑制剂selumetinib明显改善复发性/进展性儿童低级别胶质瘤预后, objectType=article, longId=207690, objectId=df0620e690db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df0620e690db, replyNumber=0, likeNumber=74, createdTime=2021-12-18, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df0620e690db, moduleTitle=Neuro Oncol：MEK-1/2抑制剂selumetinib明显改善复发性/进展性儿童低级别胶质瘤预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df0620e690db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995614, encodeId=d02f199561417, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Brit J Cancer：mTORC1/2抑制剂sapanisertib 在肾癌、子宫内膜癌或膀胱癌扩张期晚期实体肿瘤的一期研究, objectType=article, longId=201242, objectId=0c6d2012422b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c6d2012422b, replyNumber=0, likeNumber=85, createdTime=2021-07-29, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c6d2012422b, moduleTitle=Brit J Cancer：mTORC1/2抑制剂sapanisertib 在肾癌、子宫内膜癌或膀胱癌扩张期晚期实体肿瘤的一期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c6d2012422b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995616, encodeId=6892199561666, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Lancet oncol：EZH2抑制剂，有望成为滤泡性淋巴瘤患者的新选择！, objectType=article, longId=201959, objectId=fc0c201959b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc0c201959b7, replyNumber=0, likeNumber=0, createdTime=2021-02-24, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc0c201959b7, moduleTitle=Lancet oncol：EZH2抑制剂，有望成为滤泡性淋巴瘤患者的新选择！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc0c201959b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995635, encodeId=85071995635cd, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=JAMA Intern Med：SGLT-2抑制剂 vs磺脲类药物对II型糖尿病患者死亡风险的影响, objectType=article, longId=213849, objectId=4ba12138498f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ba12138498f, replyNumber=0, likeNumber=90, createdTime=2021-11-29, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ba12138498f, moduleTitle=JAMA Intern Med：SGLT-2抑制剂 vs磺脲类药物对II型糖尿病患者死亡风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ba12138498f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995626, encodeId=2af21995626db, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=BMJ：SGLT-2抑制剂或GLP-1受体激动剂治疗糖尿病的临床优势, objectType=article, longId=205766, objectId=c84a205e66fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c84a205e66fd, replyNumber=0, likeNumber=112, createdTime=2021-06-11, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c84a205e66fd, moduleTitle=BMJ：SGLT-2抑制剂或GLP-1受体激动剂治疗糖尿病的临床优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c84a205e66fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995630, encodeId=69c619956307a, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Stroke：SGLT2抑制剂对糖尿病肾病患者卒中和房颤的影响, objectType=article, longId=210247, objectId=eae121024e21, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eae121024e21, replyNumber=0, likeNumber=94, createdTime=2021-10-24, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eae121024e21, moduleTitle=Stroke：SGLT2抑制剂对糖尿病肾病患者卒中和房颤的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eae121024e21)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995624, encodeId=3baf199562455, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Diabetes Obes Metab：SGLT2抑制剂与DPP4抑制剂治疗患者心衰风险比较, objectType=article, longId=204761, objectId=2bc7204e618a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2bc7204e618a, replyNumber=0, likeNumber=100, createdTime=2021-06-22, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2bc7204e618a, moduleTitle=Diabetes Obes Metab：SGLT2抑制剂与DPP4抑制剂治疗患者心衰风险比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2bc7204e618a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995615, encodeId=abd61995615c3, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Lancet oncol：EZH2抑制剂（EPZ-643）治疗上皮样肉瘤的疗效和安全性, objectType=article, longId=201956, objectId=2c322019565b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c322019565b, replyNumber=0, likeNumber=90, createdTime=2021-02-03, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c322019565b, moduleTitle=Lancet oncol：EZH2抑制剂（EPZ-643）治疗上皮样肉瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c322019565b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995603, encodeId=63891995603bc, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Lancet：P2Y12抑制剂能够挑战阿司匹林动脉粥样硬化二级预防的地位吗？, objectType=article, longId=196863, objectId=d648196863d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d648196863d0, replyNumber=0, likeNumber=87, createdTime=2021-04-11, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d648196863d0, moduleTitle=Lancet：P2Y12抑制剂能够挑战阿司匹林动脉粥样硬化二级预防的地位吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d648196863d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995605, encodeId=90e2199560560, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=SGLT2抑制剂Farxiga喜获FDA快速通道称号，以降低心力衰竭或心血管死亡住院风险, objectType=article, longId=197735, objectId=bb3a19e7357e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb3a19e7357e, replyNumber=0, likeNumber=105, createdTime=2020-09-04, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb3a19e7357e, moduleTitle=SGLT2抑制剂Farxiga喜获FDA快速通道称号，以降低心力衰竭或心血管死亡住院风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb3a19e7357e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995631, encodeId=f68b1995631cb, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=J Clin Oncol：ROCK2抑制剂贝鲁地尔可有效治疗难治性慢性移植物抗宿主病, objectType=article, longId=210383, objectId=687e210383ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=687e210383ae, replyNumber=0, likeNumber=75, createdTime=2022-01-20, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=687e210383ae, moduleTitle=J Clin Oncol：ROCK2抑制剂贝鲁地尔可有效治疗难治性慢性移植物抗宿主病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=687e210383ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995609, encodeId=64e31995609ed, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle= J Clin Oncol：MEK1/2抑制剂Binimetinib治疗低级别浆液性卵巢癌的疗效, objectType=article, longId=199949, objectId=9c171999498a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c171999498a, replyNumber=0, likeNumber=63, createdTime=2021-08-06, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c171999498a, moduleTitle= J Clin Oncol：MEK1/2抑制剂Binimetinib治疗低级别浆液性卵巢癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c171999498a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995608, encodeId=e6a1199560850, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=鞘氨醇激酶2抑制剂Opaganib治疗COVID-19：II/III期研究已在墨西哥获得批准, objectType=article, longId=199330, objectId=176519933069, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=176519933069, replyNumber=0, likeNumber=72, createdTime=2021-06-21, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=176519933069, moduleTitle=鞘氨醇激酶2抑制剂Opaganib治疗COVID-19：II/III期研究已在墨西哥获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=176519933069)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995629, encodeId=d465199562987, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=新版医保目录自3月1日起执行，原研SGLT2抑制剂（艾托格列净）价格再创新低！, objectType=article, longId=208138, objectId=ca0a2081382a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca0a2081382a, replyNumber=0, likeNumber=70, createdTime=2021-07-16, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca0a2081382a, moduleTitle=新版医保目录自3月1日起执行，原研SGLT2抑制剂（艾托格列净）价格再创新低！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca0a2081382a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995620, encodeId=a218199562099, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Circulation：SGLT2抑制剂恩格列净也具有利尿作用, objectType=article, longId=202871, objectId=fd232028e1c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd232028e1c1, replyNumber=0, likeNumber=80, createdTime=2021-08-22, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd232028e1c1, moduleTitle=Circulation：SGLT2抑制剂恩格列净也具有利尿作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd232028e1c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

2抑制剂

2020-05-29

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

美国FDA授予Bcl-2抑制剂APG-2575第五个孤儿药称号，用以治疗滤泡性淋巴瘤（FL）

2021-07-28

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

亚盛医药APG-2575临床优势初显，国内首家Bcl-2抑制剂用于CLL/SLL前景无限

2022-04-30

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

NEJM：谷氨酰胺转胺酶2抑制剂治疗乳糜泻概念验证研究获得成功

2021-11-19

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

SGLT2抑制剂Forxiga获得欧盟和英国的批准，用于治疗慢性肾病

2021-10-07

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

JAHA：2型糖尿病患者的钠-葡萄糖协同转运蛋白2抑制剂、全因死亡率和心血管结局

2022-01-19

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Neuro Oncol：MEK-1/2抑制剂selumetinib明显改善复发性/进展性儿童低级别胶质瘤预后

2021-12-18

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Brit J Cancer：mTORC1/2抑制剂sapanisertib 在肾癌、子宫内膜癌或膀胱癌扩张期晚期实体肿瘤的一期研究

2021-07-29

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Lancet oncol：EZH2抑制剂，有望成为滤泡性淋巴瘤患者的新选择！

2021-02-24

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

JAMA Intern Med：SGLT-2抑制剂 vs磺脲类药物对II型糖尿病患者死亡风险的影响

2021-11-29

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

BMJ：SGLT-2抑制剂或GLP-1受体激动剂治疗糖尿病的临床优势

2021-06-11

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Stroke：SGLT2抑制剂对糖尿病肾病患者卒中和房颤的影响

2021-10-24

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Diabetes Obes Metab：SGLT2抑制剂与DPP4抑制剂治疗患者心衰风险比较

2021-06-22

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Lancet oncol：EZH2抑制剂（EPZ-643）治疗上皮样肉瘤的疗效和安全性

2021-02-03

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Lancet：P2Y12抑制剂能够挑战阿司匹林动脉粥样硬化二级预防的地位吗？

2021-04-11

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

SGLT2抑制剂Farxiga喜获FDA快速通道称号，以降低心力衰竭或心血管死亡住院风险

2020-09-04

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

J Clin Oncol：ROCK2抑制剂贝鲁地尔可有效治疗难治性慢性移植物抗宿主病

2022-01-20

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

J Clin Oncol：MEK1/2抑制剂Binimetinib治疗低级别浆液性卵巢癌的疗效

2021-08-06

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

鞘氨醇激酶2抑制剂Opaganib治疗COVID-19：II/III期研究已在墨西哥获得批准

2021-06-21

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

新版医保目录自3月1日起执行，原研SGLT2抑制剂（艾托格列净）价格再创新低！

2021-07-16

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Circulation：SGLT2抑制剂恩格列净也具有利尿作用

2021-08-22

科室
- - 订阅+
  - 更多科室
工具
服务